Findings are based on a study of 88 men and 78 women with ANCA-associated vasculitis with glomerulonephritis and severe kidney disease at diagnosis.

Patients with vs without ANCA-associated vasculitis are significantly more likely to die after kidney transplantation and to experience postoperative infection. Patients with ANCA-associated ...

Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 ...

May 2, 2024 Amgen Inc. beats earnings expectations. Reported EPS is $3.96, expectations were $3.88. Amgen Inc. isn’t one of ...

Amgen AMGN reported first-quarter 2024 adjusted earnings of $3.96 per share, which beat the Zacks Consensus Estimate of $3.76. Earnings declined 1% year over year due to higher operating costs and ...

Amgen's shares surge on positive phase 2 trial results for obesity candidate MariTide, increasing its potential as a strong ...

Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024. "With many of our innovative products delivering strong growth and promising new medicines advancing through our ...

Patients with vs without ANCA-associated vasculitis are significantly more likely to die after kidney transplantation and to experience postoperative infection. Patients with ANCA-associated ...

TAVNEOS (avacopan), approved by the FDA as an adjunctive treatment of ANCA-associated vasculitis, is a first-in-class, orally administered small molecule that employs a novel, highly targeted mode of ...